GEMO, a national resource to study genetic modifiers of breast and ovarian cancer risk in BRCA1 and BRCA2 pathogenic variant carriers

Authors : Fabienne Lesueur, Noura Mebirouk, Yue Jiao, et al., on behalf of GEMO Study Collaborators

Front Oncol. 2018 Oct 31;8:490. doi: 10.3389/fonc.2018.00490. eCollection 2018.

Experts group or program : Groupe génétique et cancer (GGC)

En savoir plus